Biomarker Elevation in Ovarian Cancer Predicts Poor Prognosis

Category: Innovation & Design · Effect: Strong effect · Year: 2026

Elevated serum levels of Vascular Endothelial Growth Factor (VEGF) are significantly associated with poorer overall survival in ovarian cancer patients.

Design Takeaway

Designers developing medical devices or therapeutic interventions for ovarian cancer should consider incorporating VEGF measurement or targeting as a key feature.

Why It Matters

Understanding the relationship between specific biomarkers and disease outcomes is crucial for developing targeted interventions and improving patient care. This insight highlights the potential for VEGF as a predictive indicator in the design of diagnostic tools and therapeutic strategies.

Key Finding

Higher levels of VEGF in the blood of ovarian cancer patients indicate a worse prognosis, particularly for overall survival, and are linked to more advanced disease.

Key Findings

Research Evidence

Aim: To assess the relationship between serum VEGF levels and the prognosis of ovarian cancer.

Method: Meta-analysis

Procedure: A comprehensive literature search was conducted across multiple databases to identify studies investigating serum VEGF levels and ovarian cancer prognosis. Data from eligible studies were extracted and analyzed using statistical software to determine the association between VEGF levels and various prognostic indicators, including overall survival and disease-free survival.

Sample Size: 9 studies

Context: Medical diagnostics and oncology

Design Principle

Biomarker correlation with disease progression can inform the design of predictive and prognostic tools.

How to Apply

Incorporate VEGF level assessment into the design of diagnostic assays or as a parameter in predictive models for ovarian cancer.

Limitations

The association with disease-free survival was not statistically significant, suggesting a need for further research to clarify its prognostic value.

Student Guide (IB Design Technology)

Simple Explanation: Measuring a protein called VEGF in the blood can help predict how well someone with ovarian cancer will do.

Why This Matters: This research shows how a specific biological marker can be used to understand and predict the course of a disease, which is vital for designing effective medical solutions.

Critical Thinking: How might the variability in measurement techniques for serum VEGF across different studies affect the reliability of this meta-analysis's conclusions?

IA-Ready Paragraph: Research indicates that elevated serum VEGF levels are a significant indicator of poorer prognosis in ovarian cancer, with a strong association to overall survival. This suggests that VEGF could serve as a critical biomarker in the design of diagnostic and prognostic tools for this disease, guiding the development of more targeted and effective therapeutic strategies.

Project Tips

How to Use in IA

Examiner Tips

Independent Variable: Serum VEGF levels

Dependent Variable: Ovarian cancer prognosis (overall survival, disease-free survival)

Controlled Variables: Stage of ovarian cancer, treatment status (pre/post-surgery)

Strengths

Critical Questions

Extended Essay Application

Source

Assessment of Serum VEGF Levels in Ovarian Cancer Prognosis: A Meta-Analysis · Clinical and Experimental Obstetrics & Gynecology · 2026 · 10.31083/CEOG44541